NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock ofU. S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| CELC | Celcuity LLC | Healthcare | Biotechnology | 3.60% |
| ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
| PRAX | Praxis Precision Medicines Inc | Healthcare | Biotechnology | 2.56% |
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 2.54% |
| QURE | Uniqure NV | Healthcare | Biotechnology | 2.43% |
| NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
| GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
| 6XC | SOLENO THERAPEUT. DL-001 | Healthcare | Biotechnology | 1.76% |
| MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.74% |
| NUVB | Nuvation Bio Inc | Healthcare | Biotechnology | 1.63% |
| MLYS | Mineralys Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | 1.58% |
| STOK | Stoke Therapeutics Inc | Healthcare | Biotechnology | 1.54% |
| GLUE | Monte Rosa Therapeutics Inc | Healthcare | Biotechnology | 1.52% |
| ARWR | Arrowhead Pharmaceuticals Inc | Healthcare | Biotechnology | 1.49% |
| MAZE | Maze Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | 1.41% |
| TRML | Tourmaline Bio Inc. | Healthcare | Biotechnology | 1.40% |
| RAPP | Rapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | 1.38% |
| VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 1.36% |
| COGT | Cogent Biosciences Inc | Healthcare | Biotechnology | 1.29% |
| UMRX | Cogent Biosciences Inc | Healthcare | Biotechnology | 1.29% |